Pharmidex's new service offering Medical Device Testing!
June 16, 2025

๐Ÿ‘‰ www.pharmidex.com/medical-device-testing-services


With over 23 years of experience in preclinical R&D, we’re expanding our capabilities to support the development and regulatory testing of innovative medical devices from biocompatibility assessments to in vitro and in vivo efficacy models.


This new service allows us to collaborate even more closely with biotech companies, CRO partners, academic innovators and medical device startups helping bring safe, effective and transformative technologies to patients faster.


Whether you're exploring a novel implant, delivery system, or diagnostic platform, our team is ready to support you at every step with the same scientific integrity and agility that Pharmidex is known for.


๐Ÿ’ก Let’s accelerate innovation, together.


Medical Device Testing

#MedicalDevices #Pharmidex #DrugDevelopment #MedicalDeviceTesting #Biotech #ScientificInnovation #RegulatorySupport #LifeSciences

April 1, 2026
We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: ๐Ÿ”ฌ Preclinical in vivo pharmacology ๐Ÿงช Bioanalysis (LC–MS/MS, qPCR, ELISA) ๐Ÿ“Š Translational and mechanistic studies ๐Ÿงซ Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.
March 26, 2026
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: ๐Ÿ“„ “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" ๐Ÿ“„ “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
March 24, 2026
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. ๐Ÿ”— Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
More Posts